CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7163 result(s)

Maraviroc (Celsentri)

Last Updated: December 8, 2010
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Maraviroc
Indications: HIV-1, treatment naïve (adult)

  • Brand Name: Celsentri
  • Manufacturer: GlaxoSmithKline
  • Project Number: SR0221-000
  • Project Status: Complete
  • Submission Type: Initial

Triple Therapy for Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Last Updated: December 7, 2010
Result type: Reports

[Adapted from Gaebel K, Blackhouse G, Robertson D, Xie F, Assasi N, McIvor A, Hernandez P, Goeree R. Triple Therapy for Moderate-to-Severe Chronic Obstructive Pulmonary Disease. (Technology report; no.127). Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010. For more information on this project, visit https://www.cadth.ca/triple...

  • Project Number: H0488-000

Positron Emission Tomography (PET) in Oncology: A Systematic Review of Clinical Effectiveness and Indications for Use

Last Updated: December 6, 2010
Result type: Reports

[Adapted from Mujoomdar M, Moulton K, Nkansah E. Positron Emission Tomography (PET) in Oncology: A Systematic Review of Clinical Effectiveness and Indications for Use. (Health Technology Inquiry Service). Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010.] Introduction In 2008, approximately 166,400 new cases of cancer were d...

  • Project Number: M0001-000

Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease: Clinical, Economic, and Budget Impact Analysis

Last Updated: December 5, 2010
Result type: Reports

[Adapted from: Hailey D, Jacobs P, Stickland M, Chuck A, Marciniuk DD, Mayers I, Mierzwinsky-Urban M. Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease: Clinical, Economic, and Budget Impact Analysis (Technology report; no.126). Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010.] For more information on this pr...

Status of Public Funding for In Vitro Fertilization in Canada and Internationally

Last Updated: December 5, 2010
Result type: Reports
Product Line: Environmental Scans

Context and Policy Issues Infertility affects 8% to 16% of reproductive age couples.1 In vitro fertilization (IVF) is an assisted reproductive technology that increases the chance of pregnancy for those who cannot conceive naturally. In the past, universal IVF has not been publicly funded in Canada.2 On average, one cycle of IVF costs about $10...

Support Services for Cardiac Rehabilitation in Canada

Last Updated: December 4, 2010
Result type: Reports
Product Line: Environmental Scans

Context and Policy Issues Cardiovascular disease is the leading cause of death and hospitalization in Canada.1More than 50% of all cardiovascular deaths are due to coronary artery disease. Cardiovascular disease accounts for more than $22 billion spent annually in Canada in health care costs and lost productivity due to disability or death.1 C...